To include your compound in the COVID-19 Resource Center, submit it here.

NICE rebuffs Kadcyla as too expensive

The U.K.'s NICE issued a final appraisal determination recommending against Kadcyla trastuzumab emtansine from Roche (SIX:ROG; OTCQX:RHHBY) to treat HER2-positive, unresectable, locally advanced or metastatic breast cancer in patients previously treated with the pharma's

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE